secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001493152-23-009935
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa Pharma FY2022 net loss $27.4M; cash raised to $12.9M; NGC-Cap Phase 2B to start H2 2023
--------------------------------------------------------------------------------

- Net loss for year ended Dec 31, 2022 was $27.4M ($1.70 per share) vs $11.4M ($0.75) in 2021, including $7.3M non-cash intangible impairment.
- Cash of $6.5M at year-end; subsequently raised $6.4M net from registered direct offering, total $12.9M expected to fund operations into Q3 2024.
- R&D expenses $11.5M (2022) vs $6.9M (2021); G&A $8.8M vs $4.7M, driven by stock-based comp and trial costs.
- FDA meeting in mid-April to discuss Next Generation Capecitabine Phase 2B trial; initiation expected H2 2023 in colorectal cancer.
- Dose escalations for NGC-Cap continue with no adverse events; Phase 2A gastroparesis trial completed, out-licensing for non-oncology assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/0001493152-23-009935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer